{"id":"levofloxacin-based-triple-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tendinopathy (fluoroquinolone class effect)"}]},"_chembl":{"chemblId":"CHEMBL33","moleculeType":"Small molecule","molecularWeight":"361.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in H. pylori. In triple therapy formulations, levofloxacin is combined with additional antimicrobial agents (typically amoxicillin and a proton pump inhibitor, or similar combinations) to achieve synergistic bacterial eradication and reduce antibiotic resistance. This combination approach targets H. pylori through multiple mechanisms simultaneously.","oneSentence":"Levofloxacin-based triple therapy combines a fluoroquinolone antibiotic with two other agents to eradicate Helicobacter pylori infection by inhibiting bacterial DNA gyrase and topoisomerase IV.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:33:55.716Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication in peptic ulcer disease"},{"name":"H. pylori-associated gastritis"}]},"trialDetails":[{"nctId":"NCT07405684","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp First-line Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":544},{"nctId":"NCT07405697","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp Rescue Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":"Helicobacter Pylori Infection","enrollment":290},{"nctId":"NCT07344506","phase":"PHASE4","title":"CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Dow University of Health Sciences","startDate":"2025-05-01","conditions":"H. Pylori Gastrointestinal Disease, H.Pylori Infection, H.Pylori Eradication Rate","enrollment":942},{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT07150286","phase":"NA","title":"Helicobacter Pylori Eradication Therapy for Immune Thrombocytopenia (ITP) Patients in Iraq","status":"COMPLETED","sponsor":"Al-Mustansiriyah University","startDate":"2024-09-01","conditions":"Immune Thrombocytopenic Purpura, HELICOBACTER PYLORI INFECTIONS","enrollment":100},{"nctId":"NCT04332848","phase":"PHASE4","title":"Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-07-28","conditions":"Helicobacter Pylori Infection","enrollment":360},{"nctId":"NCT06275204","phase":"","title":"H. Pylori Screen-and-treat Study in a Population of Young Adults","status":"RECRUITING","sponsor":"University of Latvia","startDate":"2024-03-04","conditions":"Gastric Cancer, H Pylori Infection, H Pylori Eradication","enrollment":6800},{"nctId":"NCT05863858","phase":"PHASE3","title":"Eradication of H. Pylori Infection With Moxifloxacin","status":"COMPLETED","sponsor":"Iyad Naeem Muhammad, PhD","startDate":"2020-06-01","conditions":"Helicobacter Pylori Infection, Helicobacter Pylori Infection, Susceptibility to","enrollment":162},{"nctId":"NCT05184491","phase":"PHASE4","title":"Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management","status":"UNKNOWN","sponsor":"National Liver Institute, Egypt","startDate":"2021-10-15","conditions":"Helicobacter Pylori","enrollment":500},{"nctId":"NCT04090021","phase":"PHASE4","title":"Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication.","status":"UNKNOWN","sponsor":"Konstantopoulio-Patission General Hospital of Nea Ionia","startDate":"2019-09-01","conditions":"Helicobacter Pylori Infection","enrollment":304},{"nctId":"NCT04061447","phase":"NA","title":"Tailored Juice-guided Eradication Therapy","status":"COMPLETED","sponsor":"Kaohsiung Medical University","startDate":"2016-02-05","conditions":"Helicobacter Pylori Infection","enrollment":182},{"nctId":"NCT03802318","phase":"NA","title":"Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-01-02","conditions":"Helicobacter Pylori Infection, Helicobacter Gastritis, Helicobacter-Associated Pyloric Ulcer","enrollment":530},{"nctId":"NCT03571230","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2018-07-01","conditions":"Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing","enrollment":400},{"nctId":"NCT02759029","phase":"NA","title":"Development of Treatment Algorithm for Eradication of Helicobacter Pylori Based on Antibiotic Susceptibility Test","status":"UNKNOWN","sponsor":"Gangnam Severance Hospital","startDate":"2016-03","conditions":"Helicobacter Pylori Infection","enrollment":123},{"nctId":"NCT02726269","phase":"PHASE3","title":"Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.","status":"COMPLETED","sponsor":"Asofarma de México S.A de C.V.","startDate":"2012-06","conditions":"Helicobacter Pylori Gastritis","enrollment":230},{"nctId":"NCT02352701","phase":"","title":"Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2012-12","conditions":"Helicobacter Infections","enrollment":320},{"nctId":"NCT01537055","phase":"PHASE4","title":"Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2012-02","conditions":"Eradication Rate for Helicobacter","enrollment":600},{"nctId":"NCT01163435","phase":"PHASE4","title":"Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2010-08","conditions":"Helicobacter Infection","enrollment":618},{"nctId":"NCT00155389","phase":"PHASE4","title":"Community-based Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2004-01","conditions":"Helicobacter Pylori Infection","enrollment":5000},{"nctId":"NCT00816140","phase":"PHASE4","title":"Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2007-06","conditions":"Helicobacter Infections","enrollment":432}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":60,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"levofloxacin-based triple therapy","genericName":"levofloxacin-based triple therapy","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levofloxacin-based triple therapy combines a fluoroquinolone antibiotic with two other agents to eradicate Helicobacter pylori infection by inhibiting bacterial DNA gyrase and topoisomerase IV. Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated gastritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}